Cargando…

IDO Targeting in Sarcoma: Biological and Clinical Implications

Sarcomas are heterogeneous malignant mesenchymal neoplasms with limited sensitivity to immunotherapy. We recently demonstrated an increase in Kynurenine Pathway (KP) activity in the plasma of sarcoma patients treated with pembrolizumab. While the KP has already been described to favor immune escape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nafia, Imane, Toulmonde, Maud, Bortolotto, Doriane, Chaibi, Assia, Bodet, Dominique, Rey, Christophe, Velasco, Valerie, Larmonier, Claire B., Cerf, Loïc, Adam, Julien, Le Loarer, François, Savina, Ariel, Bessede, Alban, Italiano, Antoine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066301/ https://www.ncbi.nlm.nih.gov/pubmed/32194552 http://dx.doi.org/10.3389/fimmu.2020.00274

Ejemplares similares

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
por: Toulmonde, Maud, et al.
Publicado: (2022)

Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
por: Spalato-Ceruso, Mariella, et al.
Publicado: (2022)

Local and Metastatic Relapse Features in Patients After a Primary Soft Tissue Sarcoma: Advocating for a Better-Tailored Follow-Up
por: Blaye, Céline, et al.
Publicado: (2019)

Gene expression profiling improves prognostication by nomogram in patients with soft‐tissue sarcomas
por: Crombé, Amandine, et al.
Publicado: (2022)

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
por: Cousin, Sophie, et al.
Publicado: (2022)

Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer
por: Bessede, Alban, et al.
Publicado: (2023)

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
por: Peyraud, Florent, et al.
Publicado: (2022)

Antitumor Effects of PRMT5 Inhibition in Sarcomas
por: Verbeke, Stéphanie, et al.
Publicado: (2023)

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
por: Savina, Marion, et al.
Publicado: (2017)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Prognostic impact of circulating tumor cells in patients with soft‐tissue sarcomas: a prospective study
por: Blanchi, Julie, et al.
Publicado: (2023)

Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome
por: Courtet, Kevin, et al.
Publicado: (2020)

Intensity harmonization techniques influence radiomics features and radiomics-based predictions in sarcoma patients
por: Crombé, Amandine, et al.
Publicado: (2020)

Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft‐tissue sarcomas
por: Blanchi, Julie, et al.
Publicado: (2023)

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
por: Larroquette, Mathieu, et al.
Publicado: (2022)

Circulating Antibodies to IDO/THO Pathway Metabolites in Alzheimer's Disease
por: Duleu, S., et al.
Publicado: (2010)

High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies
por: Toulmonde, Maud, et al.
Publicado: (2020)

Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers
por: Puccetti, Paolo, et al.
Publicado: (2015)

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)

ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case–control study—study protocol
por: Lacourt, Aude, et al.
Publicado: (2019)

ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status
por: Laroche-Clary, Audrey, et al.
Publicado: (2020)

Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison
por: Penel, Nicolas, et al.
Publicado: (2023)

LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications
por: Ben-Ami, Eytan, et al.
Publicado: (2020)

Targeting epigenetics in sarcomas through EZH2 inhibition
por: Italiano, Antoine
Publicado: (2020)

Patterns of care and outcome of CIC‐rearranged sarcoma patients: A nationwide study of the French sarcoma group
por: Brahmi, Mehdi, et al.
Publicado: (2022)

Targeting ERBB2 mutations in solid tumors: biological and clinical implications
por: Cousin, Sophie, et al.
Publicado: (2018)

The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy
por: Crombé, Amandine, et al.
Publicado: (2022)

New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
por: Roulleaux-Dugage, Matthieu, et al.
Publicado: (2023)

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study
por: Bompas, Emmanuelle, et al.
Publicado: (2018)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
por: Laroche-Clary, Audrey, et al.
Publicado: (2017)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study
por: Verschoor, Arie Jan, et al.
Publicado: (2020)

Systematic review of phase‐I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research
por: Felix, Arthur, et al.
Publicado: (2021)

Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades
por: Toulmonde, Maud, et al.
Publicado: (2023)

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans
por: Napolioni, Valerio, et al.
Publicado: (2019)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas
por: Groothuis, Patrick, et al.
Publicado: (2021)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1givppf5lho87rnd2j7oa4e501